Sahm Adrangi: The Mastermind Behind Kerrisdale

Whenever there is some misunderstanding in the market, this financial expert Mr. Sahm Adrangi has been on the forefront of dissolving doubts. He is well known for his short selling and publishing various researches on issues that revolve around stocks especially the ones that have hyped very high. The research that Sahm Adrangi does is meant to help investors drop some misconceptions of certain companies and their underlying business prospects. His view is posted on Kerrisdale’s website as well as on twitter. He serves as the Chief Investment Officer in the firm which he founded in 2009 with only $1 million and by July 2017, it had grown to manage $150 million.

Sahm Adrangi was initially heard when he exposed the fraudulent companies in China like China Marine Food Group, Lihua International, and China-Biotics among others. Recently, one of his target areas together with Kerrisdale firm is biotechnology, telecommunications and mining sectors of which he has published researches on several companies. He started his career at Deutsche Bank, Longacre Management, and Chanin Capital Partners. He studied at Yale University for BA in Economics. He has held several conferences as the speaker, appeared in various publications and in several interviews at CNBC.

Sahm Adrangi has published negative news in the Kerrisdale Capital website some of which include their short position in The St. Joe Company (NYSE: JOE) which is a real estate development company that wants to transform desolate land in Panama beach into an attractive site for businesses and the retirees. According to Sahm Adrangi, the investors will continue waiting even longer for any progress to commence.

There has been also a negative report about Proteostasis Therapeutics drug PTI-428 which the financial expert says that the release of the drug is uncertain because it’s encountering issues with the final stage 3 of FDA approval. He also feels that the company is overvaluing itself because it is basing their pricing on low-quality information.

Sahm Adrangi also had a short position on KODAKOne and KODAKCoin which he terms them as flawed and will never offer benefits to its shareholders. Consequently, he said the stock of the company has hyped unjustifiably by 187% just after the partnership was announced. The poor capital structures will still remain even after the ICO craze.

https://endpts.com/kerrisdales-sahm-adrangi-leads-a-brutal-new-biotech-short-attack-as-trial-results-loom/